MSKCC_Motzer_Score_guideline v.1
An assessment score used for metastatic renal cell carcinoma (RCC) to predict survival based on clinical and laboratory data in metastatic RCC patients.
To assist clinicians in discussions about prognosis for patients with metastatic RCC and can be used as a stratification factor in clinical trials.
Use for estimating prognosis of patients with metastatic RCC. Note: Always correct calcium concentration for low albumin before scoring. MSKCC/Motzer Score variables and assigned points: - Time from diagnosis to systemic treatment <1 year: No=0, Yes=1 - Hemoglobin < Lower Limit of Normal: No=0, Yes=1 - Calcium >10mg/dL (>2.5 mmol/L): No=0, Yes=1 - LDH > 1.5x Upper Limit of Normal: No=0, Yes=1 - Performance status <80% (Karnofsky): No=0, Yes=1 MSKCC/Motzer Score formula: Addition of selected points, as above. MSKCC/Motzer Score: score 0= Risk good = Median survival 20 months score 1-2= Risk Intermediate= Median survival 10 months score ≥3= Risk High= Median survival 4 months
Not to be used for making decisions about treatment.
1. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530. PMID: 10561319. 2. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 Jan 1;20(1):289-96. doi: 10.1200/JCO.2002.20.1.289. PMID: 11773181. 3. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004 Feb 1;22(3):454-63. doi: 10.1200/JCO.2004.06.132. PMID: 14752067. 4. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005 Feb 1;23(4):832-41. doi: 10.1200/JCO.2005.05.179. PMID: 15681528. 5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1. PMID: 19487381; PMCID: PMC3646307. 6. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013 Feb;14(2):141-8. doi: 10.1016/S1470-2045(12)70559-4. Epub 2013 Jan 9. PMID: 23312463; PMCID: PMC4144042.
OBSERVATION.mskcc_motzer.v0, EVALUATION.mskcc_motzer_assessment.v0
